scholarly journals Combined oral contraception and treatment of new coronavirus infection (COVID-19): drug interaction issues

2021 ◽  
pp. 30-39
Author(s):  
O. A. Limanova ◽  
O. A. Gromova ◽  
L. E. Fedotova
Keyword(s):  
Drug Interaction ◽  
Oral Contraceptives ◽  
Female Body ◽  
Oral Contraception ◽  
Combined Oral Contraceptives ◽  
Coronavirus Infection

Combined oral contraception and treatment of new coronavirus infection (COVID-19): issues of drug interaction This article examines the interaction of combined oral contraceptives with drugs recommended in the treatment of new coronavirus infection (COVID-19) at the pharmacodynamic and pharmacokinetic levels, with an assessment of the effectiveness and safety of therapy for the female body.

Combined oral contraceptives and treatment of new coronavirus infection (COVID-19): aspects of drug interactions

2021 ◽  
Vol 19 (1) ◽  
pp. 149-158
Author(s):  
O.A. Limanova ◽  
◽  
L.E. Fedotova ◽  
O.A. Gromova ◽  
◽  
...  
Keyword(s):  
Drug Interactions ◽  
Oral Contraceptives ◽  
Ethinyl Estradiol ◽  
Antihypertensive Drugs ◽  
Efficacy And Safety ◽  
Antiinflammatory Drugs ◽  
Combined Oral Contraceptives ◽  
Chlormadinone Acetate ◽  
Coronavirus Infection ◽  
Oral Hypoglycemic Drugs

This article discusses the problem of drug interactions between combined oral contraceptives on the example of Belara® (30 μg of ethinyl estradiol + 2 mg of chlormadinone acetate; Gedeon Richter, Hungary) and medications recommended for the treatment of new coronavirus infection (COVID-19) and concomitant disorders at the pharmacodynamic and pharmacokinetic levels with an assessment of the efficacy and safety of therapy for females. We described safe, potentially dangerous, and dangerous combinations of these drugs. Key words: new coronavirus infection (CAVID-19), combined oral contraceptives, antiviral drugs, antibacterial drugs, antiinflammatory drugs, anticoagulants, migraine drugs, antihypertensive drugs, oral hypoglycemic drugs, essential micronutrients, pharmacodynamic and pharmacokinetic interactions

scholarly journals How to reduce the number of side effects produced by COCs and improve adherence: simple tips for practitioners

2016 ◽  
pp. 10-13
Author(s):  
G. B. Dikke
Keyword(s):  
Side Effects ◽  
Oral Contraceptives ◽  
Low Dose ◽  
Oral Contraception ◽  
Combined Oral Contraceptives ◽  
Mineral Supplements ◽  
Common Causes ◽  
Natural Hormones

The frequency and severity of side effects induced by the use of combined oral contraceptives (COCs) are the most common causes of withdrawal (64.4%). Better adherence can be achieved through adequate counselling on the choice of contraception and use of extended-regimen low-dose COCs with estrogen component and natural hormones containing novel selective progestins (dienogest, drospirenone) with minimum side effects. The choice of vitamin and mineral supplements based on the relevant micronutrient disbalance in women using COCs and "quick starting" could also contribute to compliance with the chosen method of oral contraception.

scholarly journals Venous thromboembolism and oral contraception

2010 ◽  
Vol 63 (5-6) ◽  
pp. 376-379 ◽  
Author(s):  
Milena Veljkovic ◽  
Jasmina Popovic
Keyword(s):  
Venous Thromboembolism ◽  
Oral Contraceptives ◽  
Absolute Risk ◽  
Oral Contraception ◽  
Dependent Manner ◽  
Substantial Impact ◽  
Combined Oral Contraceptives ◽  
Increased Risk ◽  
The Absolute ◽  
Dose Dependent

Introduction. Because of their safety and efficacy, oral contraceptives are available without prescription in many countries. Monophasic combined oral contraceptives are a combination of estrogen and progestin taken in constant amounts. Venous thromboembolism. Combined oral contraceptives slightly increase the risk of venous thromboemolism, but this event is very rare among non-pregnant women of reproductive age. The absolute risk rises with age, obesity, recent surgery and certain forms of thrombophilia. The estrogen component of combined oral contraceptives increases the synthesis of several coagulation factors in a dose-dependent manner. Changes of most of these parameters are very small and there is no evidence that they have any effect upon the clinical risk of developing venous thrombosis. If a woman has an inherited coagulation disorder that increases her risk of developing thrombosis, the risk is increased several fold if she ingests estrogen containing oral contraception. Conclusion. The increased risk of venous thromboembolism associated with combined oral contraceptives should have little impact on healthy women, but may have substantial impact on women with a history of thromboembolism. Combined oral contraceptive use increases the risk of venous thromboembolosm in a dose-dependent manner. The absolute risk of venous thromboembolism rises with age, obesity, recent surgery and certain forms of thrombophilia, as well.

Migraine and oral contraception

1987 ◽  
Vol 25 (24) ◽  
pp. 95-96
Keyword(s):  
Epidemiological Study ◽  
Oral Contraceptives ◽  
Oral Contraception ◽  
Combined Oral Contraceptives ◽  
Medical Factors ◽  
Contraceptive Choice

In our article on medical factors in contraceptive choice1 we did not consider whether migraine should limit the prescription of combined oral contraceptives. A relationship has long been suspected and a good epidemiological study is long overdue.

Benefits and risks of oral contraception

2010 ◽  
pp. 2191-2195
Author(s):  
John Guillebaud
Keyword(s):  
Colorectal Cancer ◽  
Oral Contraceptive ◽  
Menstrual Cycle ◽  
Oral Contraceptives ◽  
Oral Contraception ◽  
Combined Oral Contraceptives

Efficacy of the ‘pill’ as an oral contraceptive—users of combined oral contraceptives (COC) must understand the importance of not lengthening the pill-free (contraception-deficient) time, and be appropriately advised if prescribed enzyme-inducing drugs. Noncontraceptive benefits of COC use—these include fewer disorders of the menstrual cycle and less risk of colorectal cancer and cancers of the ovary and endometrium, which may sometimes provide the principal indication for prescription....

Platelet Adhesiveness in Symptomatic Women Taking Oral Contraceptives

1971 ◽  
Vol 26 (03) ◽  
pp. 426-430 ◽  
Author(s):  
T. F Zuck ◽  
J. J Bergin ◽  
Jane M. Raymond ◽  
W. R Dwyre ◽  
D. G Corby
Keyword(s):  
Oral Contraceptives ◽  
Platelet Adhesiveness ◽  
Combined Oral Contraceptives ◽  
Increased Risk ◽  
Normal Women ◽  
Asymptomatic Women

SummaryPlatelet adhesiveness to glass was determined in several groups of women. Increases were found in women developing thrombovascular symptoms while taking combined oral contraceptives, compared to both normal women and asymptomatic users of oral contraceptives. Despite this increase, overlap of the groups did not permit discrimination between symptomatic and asymptomatic women. However, it is possible, that in concert with other coagulation changes, platelet adhesiveness to glass may prove adjunctive in defining women at increased risk of developing thrombovascular symptoms while taking oral contraceptives, and further define the mechanism of the increased risk.

Sign in / Sign up

Export Citation Format

Share Document